Patients description (Denmark)
| Patients at randomisation | Web N=117 | Control N=116 | p Value | |
| Gender | ||||
| Male, N (%) | 57 (48.7) | 35 (30.2) | 0.005* | |
| Female, N (%) | 60 (51.3) | 81 (69.8) | ||
| Total | 117 | 116 | ||
| Age at diagnosis, median (range) | 33 (3–66) | 35 (14–65) | ns | |
| Age at inclusion, median (range) | 41 (21–69) | 48 (21–69) | 0.01† | |
| Disease duration (years), median (range) | 4 (0–45) | 6 (0–37) | ns | |
| Disease extension at diagnosis, N, (%) | ||||
| Proctitis | 31 (26.5) | 29 (25) | ||
| Left sided | 60 (51.3) | 70 (60.3) | ns | |
| Pancolitis | 26 (22.2) | 17 (14.7) | ||
| Patients at baseline | Web N=105 | Control N=106 | P-Value | Historical control N=106 |
| Gender | ||||
| Male, N (%) | 52 (49.5) | 33 (31.1) | 40 (37.7) | |
| Female, N (%) | 53 (50.5) | 73 (68.9) | 0.008 | 66 (62.3) |
| Total | 105 | 106 | 106 | |
| Age at diagnosis, median (range) | 33 (3–66) | 35 (14–65) | ns | 32 (15–68) |
| Age at inclusion, Median (range) | 40 (21-69) | 44 (21–69) | 0.03 | 40 (18–69) |
| Disease duration (years) median (range) | 4 (0–45) | 6 (0–37) | ns | 3 (0–42) |
| Disease extension, N (%) | ||||
| Proctitis | 24 (22.9) | 25 (23.6) | 44 (41.5) | |
| Left sided | 57 (54.3) | 67 (63.2) | ns | 40 (37.7) |
| Pancolitis | 24 (22.9) | 14 (13.2) | 22 (20.8) | |
| SCCAI, median (range) | 1 (0–10) | 1 (0–11) | ns | Not recorded |
| 5-ASA treatment systemic, N (%) | ||||
| Asacol | 78 (74.3) | 68 (64.2) | 56 (52.8) | |
| Pentasa | 8 (7.6) | 7 (6.6) | 14 (13.2) | |
| Dipentum | 2 (1.9) | 4 (3.8) | ns | 0 (0) |
| Premid | 2 (1.9) | 2 (1.9) | 0 (0) | |
| Salazopyrin | 3 (2.9) | 6 (5.7) | 8 (7.5) | |
| Mezavant | 0 (0) | 0 (0) | 0 (0) | |
| None | 12 (11.4) | 19 (17.9) | 28 (26.4) | |
| Suppositories, N (%) | ||||
| Asacol | 3 (2.9) | 2 (1.9) | 1 (0.9) | |
| Pentasa | 12 (11.4) | 9 (8.5) | ns | 5 (4.7) |
| Mesasal | 3 (2.9) | 1 (0.9) | 1 (0.9) | |
| Prednisolon | 1 (1.0) | 0 (0) | 4 (3.8) | |
| None | 86 (81.9) | 94 (88.7) | 95 (89.6) | |
| Enema/Foam, N (%) | ||||
| Asacol | 4 (3.8) | 4 (3.8) | 1 (0.9) | |
| Pentasa | 7 (6.7) | 6 (5.7) | ns | 0 (0) |
| Colifoam | 4 (3.8) | 4 (3.8) | 0 (0) | |
| Pred-Clysma | 0 (0) | 0 (0) | 2 (1.9) | |
| None | 90 (85.7) | 92 (86.8) | 103 (97.2) | |
| BMI, Median (range) | 24 (18–42) | 24 (18–46) | ns | Not recorded |
| Smoking (%) | ||||
| Non-smoker | 39 (37.1) | 46 (43.4) | ||
| Active smoker | 19 (18.1) | 18 (17) | ns | Not recorded |
| Ex-smoker | 47 (44.8) | 42 (39.6) | ||
| Marital status (%) | ||||
| Married | 69 (65.7) | 82 (77.4) | ||
| Single | 36 (34.3) | 24 (22.6) | ns | Not recorded |
| Education (%) | ||||
| Academic | 33 (31.4) | 29 (27.4) | ||
| Other education | 55 (52.4) | 64 (60.4) | ||
| During education | 16 (15.2) | 5 (4.7) | ns | Not recorded |
| No education | 1 (1.0) | 8 (7.5) | ||
| Occupation (%) | ||||
| Paid | 82 (77.1) | 86 (81.1) | ||
| Unpaid | 1 (1.0) | 4 (3.7) | ns | Not recorded |
| Support | 15 (14.3) | 6 (5.7) | ||
| Pensioner | 7 (6.7) | 10 (9.4) | ||